NEW DELHI: Haleon, formerly GSK Consumer Healthcare, will invest about Rs 2,000 crore (£175 million) to establish its first manufacturing facility in India, underscoring the country’s position as one of the company’s fastest-growing markets globally.The greenfield facility to come up at Pithampur (Madhya Pradesh), marks a significant investment in India’s consumer health sector and reinforces Haleon’s long-term commitment to the country as a strategic growth market, the company said.The company currently relies on third-party contract manufacturers in India, making this its first owned manufacturing facility in the country, and the first in South Asia.The plant focused primarily on oral-health products will support govt’s ‘Make in India’ vision, strengthen supply chain resilience, drive domestic value addition, and support exports to other key markets, according to Kedar Lele, CEO India and President India Subcontinent, Haleon said.It will also help Haleon to reach one billion more consumers by 2030, which include 300 million in India.The facility is designed on Haleon’s new global advance blueprint and is set to feature future-ready automated manufacturing capabilities. It is expected to be operational by 2029–30, enabling Haleon to meet growing demand across domestic and international markets.In India, the company’s portfolio includes oral health, digestive health, pain relief and respiratory (PRS), and vitamins, minerals and supplements, with brands including Sensodyne, Eno, Otrivin, Centrum, Iodex and Crocin.